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Abstract 
Lipoxin A4 (LXA4) is an endogenous lipid mediator that requires transcellular metabolic traffic for 
its synthesis. The targets of LXA4 on neutrophils are well described, contributing to attenuate 
inflammation. However, the effects of lipoxins on macrophage are less known, in particular the 
action of LXA4 on the regulation of apoptosis of these cells. Our data show that pre-treatment of 
human or murine macrophages with LXA4 at the concentrations prevailing in the course of 
resolution of inflammation (nanomolar range) inhibit significantly the apoptosis induced by 
staurosporine, etoposide and S-nitrosoglutathione or by more pathophysiological stimuli, such as 
LPS/IFNγ challenge. The release of mitochondrial mediators of apoptosis as well as the activation 
of caspases was abrogated in the presence of LXA4. In addition to this, the synthesis of reactive 
oxygen species induced by staurosporine was attenuated and anti-apoptotic proteins of the Bcl-2 
family accumulated in the presence of lipoxin. Analysis of the targets of LXA4 identified an early 
activation of the PI3K/Akt and ERK/Nrf-2 pathways that was required for the observation of the 
antiapoptotic effects of LXA4. These pathways activated in response to LXA4 contribute to the 
upregulation of the antiapoptotic proteins of the Bcl-2 family and to the transcription of 
cytoprotective genes under the control of the ERK/Nrf-2 signaling. These data suggest that the 
LXA4 released after recruitment of neutrophils to sites of inflammation exerts a protective effect on 
macrophage viability that might contribute to a better resolution of inflammation.  
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INTRODUCTION 
Regulation of apoptosis of immune cells is a critical stage during inflammation, because 
when the injury is over, accomplishment of a correct resolution, mainly through apoptotic death, 
prevents the development of chronic inflammatory diseases [1,2,3]. During this process, 
neutrophils are quickly recruited to sites of infection where they have a very short life and die 
rapidly via apoptosis [4,5]. Macrophages arrive later to phagocyte apoptotic-cells and pathogens in 
the affected area. Thus, for an effective resolution of the inflammatory process, it is important that 
macrophages have a sufficient life span to clear the inflamed area (2-3 days).  
Lipoxins (LXs) are endogenous eicosanoids which are released during the resolution phase 
of inflammation, in the nanomolar range [6,7]. LXs are mainly generated by transcellular 
metabolism from arachidonic acid depending on the cellular context [8,9]. In mammals, 
lipoxygenase enzymes (LOX) generate two main native products, lipoxin A4 (LXA4) and B4 
(LXB4) being the most studied LXA4, which exerts potent anti-inflammatory actions modulating 
leukocyte trafficking and promoting phagocytic clearance of apoptotic cells [10,11,12]. The effects 
of lipoxins as lipid mediators with potent anti-inflammatory actions are well documented, but their 
role in apoptosis remains controversial [13]. For instance, it has been described an apoptotic effect 
in fibroblasts after treatment with LXA4 at micromolar concentrations [14], whereas it has been 
also reported that this compound inhibits peroxynitrite formation in leukocytes [15], reduces 
colonocyte apoptosis [16] and promotes survival of  retinal pigment epithelial cells [17]. Therefore, 
the precise role of lipoxins as modulators of apoptosis remains elusive and appears to be dependent 
on the cell type and on the LXA4 concentration. Given the lack of studies concerning the role of 
LXA4 in macrophage apoptosis and considering the importance of this immune cell in 
inflammation, we have investigated the effect of native LXA4 on macrophage apoptosis using 
staurosporine, etoposide and GSNO as strong apoptosis-inducers in many cell types [18,19,20], as 
well as LPS/IFNγ as a more pathophysiological condition. Our results show that concentrations of 
LXA4 in the nanomolar range prevent apoptosis in murine and human macrophages through a 
mechanism consistent with changes in the levels of apoptosis-related proteins, favoring an anti-
apoptotic environment, and a blockade of early apoptotic signaling, that involves the suppression of 
the release of mitochondrial-dependent apoptotic mediators and caspases activation. Moreover, our 
data show that lipoxin treatment of macrophages promotes a rapid activation of the PI3K/Akt 
signaling that is relevant for protection against apoptosis, in agreement with previous work 
describing up-regulation of antiapoptotic genes by this pathway, such as Mcl-1 [21,22]. In addition 
to this, treatment of macrophages with LXA4 induced ERK/Nrf-2 activation, being Nrf-2 a 
transcription factor that regulates the expression of ca. 100 cytoprotective genes that share in 
common a sequence termed antioxidant response element (ARE) [23,24], and contributes to the 
anti-oxidant defense pathway in many cells [25,26,27]. Activation of this pathway in macrophages 
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by LXA4 decreased staurosporine-induced apoptosis, without affecting the activity of JNK and p38 
MAPKs.  
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MATERIALS AND METHODS 
Materials. Staurosporine, MG132, LY294002 and PD098059 were from Calbiochem (San Diego, 
CA); LXA4 and 15-epi-LXA4 were from Cayman (Ann Arbor, MI) or Calbiochem; etoposide, LPS, 
PMA and GSNO were from Sigma (St. Louis, MO); IFNγ was form PeProtech (UK); Jo2 was from 
BD (CA). N-t-Boc-Phe-Leu-Phe-Leu-Phe (BocPLP), a formyl peptide lipoxin-receptor competitive 
antagonist was from Bachem (Bubendorf, CH); antibodies were from Santa Cruz Biotech (Santa 
Cruz, CA), BD Transduction Laboratories (San Jose, CA), or Cell Signaling Technology (Danvers, 
MA). Fluorescent probes were from Molecular Probes (Eugene, OR). Other reagents were from 
Roche (Mannheim, Germany) or Sigma. Tissue culture dishes were from Falcon (Lincoln Park, 
NJ), and culture media were from Invitrogen (Carlsbad, CA). 
Animals. Seven-week old male wild-type C57BL/6 mice and nrf-2-knockout littermates [28] were a 
generous gift from Dr A. Cuadrado (IIBM, Madrid). Mice were housed at RT under 12h light/dark 
cycle and food and water was provided ad libitum. Animals were cared for according to a protocol 
approved by the Ethical Committee of our institution (following 86/609/EEC, 2003/65/EC 
directives).  
Isolation of human monocytes. PBMCs were isolated from blood of healthy donors by 
centrifugation on Ficoll-Hypaque Plus (Amershan Biosciences, UK) following the manufacturers’ 
protocol. Cells were maintained for 2 h to a density of 106 cells/ml in DMEM supplemented with 
antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin). After this period, the supernatant 
was removed and adherent cells were cultured in the same medium supplemented with 10% heat-
inactivated FBS. Purity of all cultures was verified by CD14+ staining; on average 87% of the cells 
presented this surface marker. Cells were maintained overnight with this medium and differentiated 
with h-MCSF (20 ng/ml, PeProtech) for 7 days followed by treatment with the indicated stimuli.  
Cell culture and transient transfections. The macrophage cell line RAW 264.7 was maintained in 
RPMI 1640 medium containing 100 U/ml penicillin, 100 μg/ml streptomycin and 10% heat-
inactivated FBS. Before experiments, the medium was challenge to 1% FBS. Elicited peritoneal 
macrophages were prepared as previously described [29] and used as indicated for the cell line. For 
transient transfections, cells were grown at 80% confluence and transfected using the Cell Line 
Nucleofector Kit V, following the manufacturer´s instructions (Amaxa). After nucleofection, cells 
were stimulated for 6h and luciferase activity was measured using a Dual Luciferase Reporter 
Assay System (Promega). The human monocytic THP-1 cells were maintained in culture with 
RPMI 1640 supplemented with 10% FBS and 20 mM HEPES. PMA (50 nM, 48h) was used to 
induce THP-1 monocytes to differentiate into macrophages. Then, the medium was changed to 
RPMI 1640 supplemented with 1% FBS and cells were stimulated for the indicated periods of time. 
Preparation of total protein cell extracts. Cells were homogenized in a medium containing 10 mM 
Tris-HCl, pH 7.5; 1 mM MgCl2, 1 mM EGTA, 10% glycerol, 0.5% CHAPS, 1 mM β-
mercaptoethanol and 0.1 mM PMSF and a protease and phosphatase inhibitor cocktail (Sigma). 
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The extracts were vortexed for 30min at 4ºC and after centrifuging for 20min at 13000g, the 
supernatants were stored at 20ºC. Protein levels were determined with Bradford reagent (Bio-Rad, 
Hercules, CA).  
Preparation of cytosolic and nuclear protein cell extracts. Stimulated cells were harvested into ice-
cold PBS, resuspended in 200 µl of cytosolic buffer (10 mM HEPES, pH 8; 10 mM KCl, 1 mM 
EDTA, 1 mM EGTA, 0.5% NP-40) and left to swell on ice for 15min. Cells were vortexed and 
centrifuged at 12000g for 30s. The pellet was resuspended in 50 µl of ice-cold nuclear buffer (20 
mM HEPES, pH 8; 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 20% glycerol) and vortexed at 4ºC 
for 30min. Following centrifugation (12000g at 4°C for 20min), the supernatant was transferred to 
a fresh tube. All buffers contained protease and phosphatase inhibitor Cocktail (Sigma). 
Cytochrome c release assay. Cell pellets were resuspended in buffer A (0.32 M sucrose, 10 mM 
Tris-HCl, 1 mM EDTA, pH 7.5, and protease inhibitor cocktail) and homogenized by repeated 
passage through a 27-G needle. Then cells were centrifuged for 15min at 4ºC and 10000g. The 
supernatants were saved as cytosolic fractions and stored at -80ºC. Pellets were resuspended again 
in buffer A and were saved as ‘particulate’ fractions containing the mitochondria and stored at        
-80ºC until cytochrome c quantification. 
Western blot analysis. Equal amounts of protein (20-50 μg) from each fraction obtained were 
loaded into a 10-12% SDS-PAGE. Proteins were size fractionated, transferred to a Hybond-P 
membrane (Amersham) and, after blocking with 5% nonfat dry milk, incubated with the 
corresponding Abs. The blots were developed by ECL protocol (Amersham) and different 
exposition times were performed for each blot with a Charged Coupling Device camera in a 
luminescent image analyzer (Molecular Imager, BioRad) to ensure the linearity of the band 
intensities. Values of densitometry were determined using Quantity One software (Bio-Rad). 
In vitro and in vivo caspase activity assays. For the in vitro determination, total cell extracts were 
prepared and supernatants were used to measure caspase activities by cleavage of specific 
substrates in accordance with the supplier´s instruction (BD, Pharmingen). Caspase activity was 
quantified fluorimetrically by following the cleavage of Ac-DEVD-AMC for caspase 3, Ac-IETD-
AFC for caspase 8 and Ac-Leu-Glu-His-Asp-AFC for caspase 9. Cell lysates were incubated for 
60min at RT with corresponding substrates and the activity was measured with excitation-emission 
wavelengths of 340-460 nm for caspase 3 and 400-480 for caspase 8 and 9. CaspGLOW 
fluorescein Active Caspases Staining kit was also used to detect activated caspases in living cells 
by fluorescence microscopy, according to manufacturer instructions (Biovision Res, CA). Briefly, 
cells were treated with the indicated stimuli and incubated in the presence of a fluorescent marker 
conjugated to FITC that irreversibly binds to activated caspases in apoptotic cells. This label allows 
for direct detection of apoptotic cells by fluorescence microscopy. 
Flow cytometry. Analysis was carried out using a FC 500 Becton Dickinson FACScan flow 
cytometer (Mountain View, CA) with a CXP Software (Beckman Coulter).  
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Cell death detection. Cells were harvested and washed in cold PBS. After centrifugation at 4ºC for 
5min and 1000g, cells were resuspended in annexin V binding buffer (10 mM Hepes, pH 7.4; 140 
mM NaCl, 2.5 mM CaCl2). Cells were labeled with annexin V-FITC solution (BD Pharmingen) 
and propidium iodide (PI) (100 μg/ml) for 15min at RT in the dark. The percentage of cells with 
hyplodiploid DNA was used as another marker of apoptosis. For DNA detection, cells were 
suspended in 0.5 ml of 100 μg/ml PI in 0.1% sodium citrate plus 0.1% Triton X-100.  
Immunofluorescence microscopy. RAW 264.7 cells were seeded into sterile 8-wells Chamber 
Slides (Falcon, Lincoln Park, NJ), 16-24h before treatment. MitoTraker Red CMXRos (50 nM, 
Molecular Probes) was added to the culture medium for 30min before washing cells with PBS 
followed by fixation with 2% paraformaldehyde for 10min. Cells were then permeabilized in iced 
methanol and incubated with 3% BSA for 30min. After incubating with a rabbit Ab against 
Apoptosis-Inducing Factor (AIF) (Santa Cruz Biotechnology) at 4ºC for 1h, cells were washed with 
PBS followed by incubating with Alexa 488 anti-rabbit secondary antibody at 4ºC for 1h at RT 
(1:500; Molecular Probes). Coverslips were mounted in Vectashield (Vector Laboratories, 
Burlingame, CA) and examined using an Espectral Leica TCS SP5 confocal microscope. Values of 
intensity fluorescence and colocalization quantification were performed with Image J software 
(NIH, Bethesda, MD).  
ROS and reactive nitrogen intermediates (RNI) determination. ROS generation in RAW 264.7 cells 
was analyzed by flow cytometry monitoring the oxidation of 2´,7´-dichlorodihydrofluorescein 
(DCFH). Cells were loaded with 0.4 μM DCFH for 30min, pelleted and resuspended in PBS 
followed by flow cytometry. RNI synthesis was determined incubating cells with 200 μM DAF-2 
diacetate.  
Microarray analysis of apoptosis-related genes. Total RNA was isolated from cells with TRIzol 
Reagent (Invitrogen, California, USA) and further cleaned up using the Qiagen RNeasy MiniKit 
(Hilden, Germany) with one step of DNAse I digestion. 3 μg of RNA were used for cDNA 
synthesis with RT2 first Standard kit (SuperArray Bioscience, Frederick, MD). The mouse 
apoptosis PCR array was performed according to the manufacturer's protocol, using the Profiler 
PCR Array System and the SYBR Green/Fluorescein qPCR master mix (SuperArray Bioscience) 
on a MyiQ Real-Time PCR System (Bio-Rad). Gene expression was compared with the web-based 
software package for the PCR Array System (http://www.superarray.com/pcr/arrayanalysis.php). 
This software automatically performs all ΔΔCt based fold-change calculations from the specific 
uploaded raw threshold cycle data. Results were analyzed as described Mayoral et al [30] and RT-
PCR of selected genes was used to validate the microarray data. 
Statistical analysis. The values in graphs correspond to the means±SD. The statistical significance 
was estimated with a Student t test for unpaired observation. Data were analyzed by the SPSS for 
Windows statistical package, version 9.0.1. 
 
8 
 
RESULTS 
LXA4 prevents stimuli-dependent apoptosis in macrophages. Preliminary studies in our laboratory 
suggested that lipoxin A4 enhanced the viability of activated macrophages. Using staurosporine as a 
potent and broad inducer of apoptosis in mammalian cells, we evaluated the ability of lipoxin to 
interfere the apoptosis induced by this drug in macrophages. Incubation for 4h of RAW 264.7 cells 
with staurosporine (200 ng/ml) increased the percentage of annexin V positive cells by 38% (Fig. 
1A). Preincubation for 2h of the cells with LXA4 in the range of concentrations found under 
inflammatory conditions resulted in a dose-dependent inhibition of the pro-apoptotic effect of 
staurosporine (EC50 250 nM). This protective action of LXA4 was mediated, at least in part, via its 
receptor since it was interfered after 1h of incubation with 1 μM BocPLP, a formyl peptide lipoxin- 
receptor antagonist [31,32], and was specific for LXA4, being the 15-epi-LXA4 derivative less 
effective (Fig. 1A). Fig. 1B shows a representative flow cytometry distribution of this annexin V 
analysis. The protective effect of lipoxin against apoptosis was confirmed by DNA size distribution 
analysis, observing a significant reduction of the hypodipliod population (Fig. 1C). When apoptosis 
was induced with etoposide (1 μM), GSNO (0.5 mM) or after LPS (500ng/ml)/IFNγ (20 ng/ml) 
challenge, treatment of cells with LXA4 significantly decreased the apoptotic response in all these 
cases, suggesting the interference with a common pro-apoptotic signaling step (Fig. 1D).  
 
Lipoxin inhibition of caspase activation and pro-apoptotic signaling in macrophages treated with 
staurosporine.  To study the antiapoptotic effect of lipoxin, the activation of caspases 3, 8 and 9 
was analyzed in cells treated with staurosporine. As Fig. 2A shows, the well-known activation of 
caspases induced after staurosporine treatment (200 ng/ml; 4h and 18h, respectively) was 
significantly impaired in the presence of LXA4. In addition to these determinations, the “in vivo” 
activation of caspases was measured using cell-permeant fluorescent probes (representative 
example for caspase 3; Fig. 2B, left panel). Fig. 2B (right panel) shows the percentage of cells with 
activated caspases 3, 8 or 9 after staurosporine treatment. LXA4 significantly reduced the 
percentage of cells with activated caspases, an effect that was in the range of that observed in cells 
treated with the broad caspase inhibitor z-VAD (20 µM).  
In view of these data, the release of pro-apoptotic mediators from the mitochondria was 
investigated since this is one of the key events in the commitment of the apoptotic response of 
macrophages. As Fig. 3 shows, the release of cytochrome c (panel A) and AIF (panel B) induced 
after staurosporine challenge was inhibited in lipoxin-pretreated-cells and both proteins were 
retained in the mitochondrial/particulate compartment. In addition to this, the oxidative stress 
induced by staurosporine in macrophages was also attenuated after lipoxin treatment, as reflected 
by the decrease in DCFH oxidation in the presence of LXA4 (Fig. 3C). Moreover, using DAF-2 as 
RNI scavenger, a dose-dependent decrease in the oxidation of this probe promoted by staurosporine 
was observed in cells pretreated with lipoxin (Fig. 3D).  
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To investigate the mechanisms mediating the anti-apoptotic effects of LXA4 in 
macrophages, the levels of apoptosis-related proteins were determined by Western blot. As Fig. 4A 
shows, treatment with LXA4 increased the levels of the anti-apoptotic proteins Mcl-1 and to a 
lesser extent those of x-IAP and Bcl-2, without affecting Bax changes upon staurosporine 
challenge. Indeed, the ratio between Mcl-1 (and also x-IAP and Bcl-2) and Bax (Fig. 4B), well 
reflected the protection against apoptosis observed in lipoxin-treated cells. To gain further insight 
into the differential apoptotic response of staurosporine-treated and lipoxin-pretreated cells, we 
used a specific mouse apoptosis microarray to compare the gene expression profile after these 
treatments. Fig. 4C summarizes the changes in the expression of genes whose transcription is 
up/down 2-folds over the threshold value, among the apoptosis-related genes analyzed. The data 
show that staurosporine did not alter significantly the expression of the majority of the genes 
analyzed (p<0.01). Moreover, using RT-PCR to confirm the array data, it was observed that, over 
the genes modified by staurosporine, LXA4 was capable to reduce significantly the expression of 
some genes, such as IL-10 (Fig. 4D), that exerts a pro-apoptotic activity in macrophages [33]. 
Indeed, lipoxin did not alter significantly the expression of most of the genes involved in 
staurosporine-induced apoptosis, suggesting the involvement of post-transcriptional mechanisms in 
its mechanism of action. 
 
Lipoxin-dependent survival involves AKT and ERK activation. The rise in Mcl-1 levels after 
LXA4 treatment suggests the activation of the PI3K/Akt pathway [21]. As Fig. 5A shows, LXA4 
promoted a rapid Akt phosphorylation in a PI3K-dependent way, as deduced by the inhibitory 
effect observed by LY294002 incubation.  In addition to this and since MAPKs are implicated in 
the regulation of basic cellular processes, such as apoptosis, survival, proliferation, and 
differentiation, and our preceding data suggest that LXA4 is influencing signaling steps upstream 
mitochondrial pro-apoptotic targeting, the effects of lipoxin on the activity of these kinases were 
investigated. As Fig. 5B,C illustrate, staurosporine induced the phosphorylation of p38 and JNK 
from 30 to 120min; however, this treatment did not activate ERK over its low basal level. LXA4 
pre-treatment did not affect p38 or JNK phosphorylation, but promoted a rapid activation of ERK 
after staurosporine challenge. Inhibition of this ERK activation with PD098059 (1 µM), or PI3K 
activity with LY294002 (10 μM) abolished the protective effect exerted by LXA4 against apoptosis 
(Fig. 5D). In addition to this, the translocation to the nucleus and activation of the transcription 
factor Nrf-2 was also observed in LXA4–pretreated cells following kinetics similar to ERK 
activation (Fig. 5E). Interestingly, unlike staurosporine, LXA4 was able to activate an ARE-
luciferase reporter gene upon transfection, whereas the ERK inhibitor PD098059 impaired this 
response, suggesting that the cytoprotective pathway dependent on Nrf-2 activity [23,24] is 
activated in response to LXA4. MG132 was used as a positive control of ARE activation (Fig. 5F). 
Finally, using peritoneal macrophages from Nrf-2 deficient mice (Fig. 5G), it was observed a 
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significant decrease in the anti-apoptotic activity mediated by LXA4. Taken together, these data 
suggest a link between Akt and ERK/Nrf-2 activation and the protective effects against apoptosis 
exerted by LXA4 in macrophages.   
 
Protection from apoptosis by lipoxin A4 of murine and human macrophages. To validate the 
results obtained in RAW 264.7 cells in other sources of macrophages, we carried out some key 
experiments in murine peritoneal macrophages. As Fig. 6A shows, the treatment with lipoxin 
promoted a rapid Akt phosphorylation in these cells that was inhibited in the presence of 
LY294002. Following the same line, challenge with staurosporine produced a rise in the phospho-
ERK levels in cells treated with lipoxin, a receptor-mediated effect, since it disappeared when these 
macrophages were pre-treated with BocPLP prior to LXA4 challenge (Fig. 6B). As in RAW 264.7 
cells, apoptosis was significantly prevented in LXA4 pretreated cells after stimulation with 
staurosporine, LPS/IFNγ or the anti-mouse FAS Jo2. In agreement with our previous data, 
inhibition of the ERK or PI3K pathways attenuated the antiapoptotic effect exerted by lipoxin (Fig. 
6C). To extent our results, we corroborated that similar effects in terms of apoptosis protection 
against staurosporine were obtained in cultured human monocyte/macrophages and in the 
monocytic cell line THP-1. These effects were also mediated by the Akt and ERK pathways as 
demonstrated using the corresponding inhibitors (Fig. 6D). LXA4 also promoted the translocation 
to the nucleus of Nrf-2 in these cells as shows in Fig. 6E being capable to maintain the 
antiapoptotic effects previously reported in murine macrophages.  
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DISCUSSION 
The present study provides evidence for a new mechanism of action of LXA4, by which 
this compound contributes to inflammation resolution, delaying apoptosis in murine and human 
macrophages. Prolonged macrophage survival is required for phagocytosis of death cells in the 
inflamed area, avoiding excessive accumulation of cellular debris into the injured tissues. Lipoxins 
are natural compounds detected in several tissues in the nanomolar range, but exhibiting a certain 
cell-specificity. In this regard, lipoxins have been involved in the pathogenic mechanism of some 
microbes. For example, in addition to the anti-apoptotic effects of LXA4 it has been described that 
this lipoxin prevents PGE2 synthesis and this strategy is used by virulent Mycobacterium 
tuberculosis strains to avoid repair of the macrophage plasma membrane and to promote necrosis at 
the time the pathogen evades macrophage function [12,34]. Therefore, although their role as anti-
inflammatory compounds is well-documented, the implication in apoptosis has been a matter of 
debate [2,5,8,35]. Opposite actions of lipoxins on the balance between survival/apoptosis have been 
reported in neutrophils when signaling through the pleiotropic formylpeptide receptor like-1/LXA4 
receptor [31]. This receptor binds a series of molecules including LXA4, acute-phase reactant 
serum amyloid A (SAA) and the glucocorticoid-inducible protein annexin-1. Whereas annexin 1 
and lipoxins accelerate resolution/apoptotic death of neutrophils via caspase 3 activation, SAA 
rescues the cells by preventing mitochondrial dysfunction [36,37,38]. In contrast to neutrophils, 
macrophages arrive later to the inflamed area and they contribute to tissue clearance. Thus, as our 
results indicate, as far as the synthesis of lipoxins occurs they act as anti-apoptotic molecules, 
preserving macrophage function during resolution. 
We previously described that the release of NO by activated macrophages contributes 
transiently to expand macrophage viability by inhibiting caspase processing and activation, via the 
formation of S-nitrosothiols in these enzymes [39]. In line with this, the results reported in this 
work stand directly on the mechanism of action of lipoxin in the resolution of inflammation. The 
data show that lipoxin pre-treatment of macrophages diminishes staurosporine, etoposide, GSNO 
and LPS/IFNγ-induced apoptosis. Moreover, in murine peritoneal macrophages and in human 
monocyte/macrophages that exhibit an apoptotic response via the Fas/FasL pathway, treatment 
with LXA4 also exhibited a protective effect. The fact that the protective effect of LXA4 against 
apoptosis was observed in human and murine primary cultures of macrophages and in macrophage 
cell lines suggests the existence of common mechanisms of response to lipoxins in these cells. The 
action of lipoxin was independent of the time of pre-treatment from 12h to 30min, prior to 
staurosporine challenge (data not shown). These data suggest that the mechanisms involved in 
protection against apoptosis are mainly regulated by short-term responses to lipoxins, rather than 
by profound changes in the expression of genes that regulate cell viability.  
The apoptosis induced by staurosporine involves essentially the mitochondrial pathway 
[18,40,41]. Activation of apoptosis-related proteins is considered a basic step into the apoptotic 
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progression being fundamental those of the Bcl-2 family, which includes both anti and pro-
apoptotic members, and other related proteins. Using microarrays of apoptosis-related genes, it was 
observed that LXA4 fails to promote changes in the expression of these genes. However, in the 
presence of lipoxin the protein levels of Bcl-2, x-IAP and Mcl-1, all anti-apoptotic proteins, were 
maintained, indicating post-transcriptional regulation. Moreover, our data show that incubation of 
macrophages with LXA4 promotes a rapid activation of the PI3K/Akt pathway that has a relevant 
role in the inhibition of apoptosis [42]. Among the antiapoptotic genes regulated through this 
pathway upregulation of Mcl-1 levels have been identified in various cell types [23,24], a situation 
also prevailing in macrophages treated with LXA4. Indeed, incubation with lipoxin preserved the 
mitochondrial integrity as deduced by the minimal release of cytochrome c and AIF to the cytosol. 
Oxidative stress is another determinant which regulates the balance between viability/apoptosis 
[25,43,44,45,46]. We have analyzed the effect of lipoxin on the liberation of some important 
reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI), using fluorescent probes. 
Our results indicate that lipoxin inhibits ROS and RNI release, reducing the oxidative stress 
associated with apoptosis. Consistent with this, lipoxin at nanomolar concentrations also 
diminishes the caspase activation induced after staurosporine treatment. This inhibitory action was 
detected for all caspases analyzed, being the most potent effect on caspase 3 and to a lesser extent 
on both caspase 8 and 9. The results from the experiments using the pan-caspase inhibitor z-VAD, 
confirmed the importance of lipoxin reduction of caspase activation, leading to similar levels of 
apoptosis in macrophages.  
In addition to this, it is known that macrophage apoptosis is controlled by a complex 
network of signaling pathways, including MAPKs pathways [45,47,48,49,50]. The present study 
provides evidence that lipoxin might affect these pathways. Incubation of macrophages with 
staurosporine induces a rapid activation of JNK and p38 MAPKs, but not of ERK, a classic 
survival pathway [51]. Interestingly, lipoxin pre-treatment was able to promote ERK 
phosphorylation in the presence of staurosporine without affecting neither JNK nor p38 activities. 
Furthermore, MAPKs pathway associates with the modulation of Antioxidant Response Elements 
(ARE)-driven gene expression via Nrf-2 activation, a transcription factor that is considered as the 
“guardian of redox homeostasis”. It has been reported that ERK activation is involved in the 
translocation of Nrf-2 to the nucleus where this transcription factor binds to the ARE motifs 
[27,52]. Nrf-2 regulates the transcription of ca. one hundred of genes involved in cytoprotection 
and regulation of oxidative stress [23]. Recently it has been described the LXA4-dependent 
apoptosis of human neutrophils involves the inhibition of myeloperoxidase-induced ERK, that 
results in a reduction in the expression of the anti-apoptotic gene Mcl-1 [53]. However, our results 
provide a new mechanism by which lipoxin impairs macrophage apoptosis, involving Nrf-2 
activation through an ERK dependent pathway [26,27,54].  
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Although multiple studies exist about the regulation of innate immunity by lipoxins, 
including SOCS2-dependent ubiquitinylation of TRAF-2 and -6 [55,56], our results demonstrate 
that LXA4 prolongs macrophages survival by: a) activation of the PI3K/Akt pathway, leading to the 
expression of antiapoptotic proteins of the Bcl-2 family;  b) activation of the ERK/Nrf-2 pathway 
upon challenge with an apoptotic stimulus, such as staurosporine; c) preservation of mitochondrial 
function and integrity, and enhancement of the anti-oxidant defense systems in cells; d) impairment 
of caspase activation due to the absence of pro-apoptotic signaling dependent on the mitochondrial 
pathway or the death-receptor pathway. Therefore, these observations provide an additional anti-
apoptotic mechanism for LXA4 in macrophages and might contribute to the establishment of a 
hitherto unrecognized potential of lipoxins for the treatment of inflammatory diseases. 
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LEGENDS TO FIGURES 
Figure 1. Lipoxin A4 attenuates apoptosis in RAW 264.7 cells. The percentage of annexin V-
positive cells was determined by flow cytometry after preincubation (2h) of macrophages with the 
indicated concentrations of epi-LXA4 or LXA4 in the absence or presence of 1 µM BocPLP (1h 
before LXA4), a lipoxin receptor antagonist, followed by apoptosis induction by 200 ng/ml of 
staurosporine or vehicle for 4h (A). Representative dot plot diagrams are shown (250 nM of LXA4) 
(B). This cell population was also analyzed by flow cytometry for nuclear DNA content (C). Cells 
were incubated with staurosporine (200 ng/ml), etoposide (1 μM) or GSNO (0.5 mM) alone or in 
combination with LXA4 for 18h, and with LPS (500 ng/ml)/IFNγ (20 ng/ml) for 48h. Apoptosis 
was determined by flow cytometry using PI labeling (D). Results show the mean±SD of four 
different experiments. *P<0.05, **P<0.01 vs. the corresponding condition in the absence of 
lipoxin. 
 
Figure 2. Lipoxin treatment impairs caspase activation in RAW 264.7 cells. Cells were treated 
for 4h or 18h with 200 ng/ml staurosporine alone or in combination with 250 nM LXA4 (2h of 
pretreatment) and the activity of caspases 3, 8 and 9 was determined in cell extracts (A) or using 
CaspGlow ‘in-cell’ caspase activation detection (B; left panel: representative images of caspase 3 
positive cells). The intensity of the cell fluorescence was digitalized and quantified with respect to 
the total cell number determined by Hoechst labeling (B, right panel). The broad apoptosis inhibitor 
z-VAD was used at 20 μM following manufacturer instructions as positive control. Results show 
the means±SD of three different experiments. *P<0.05, **P<0.01 vs. the corresponding condition 
in the absence of lipoxin. 
 
Figure 3. Release of mitochondrial apoptotic mediators and oxidative stress were reduced by 
lipoxin treatment in RAW 264.7. Cells were pretreated for 2h with LXA4 (250 nM) and 
challenged with 200 ng/ml of staurosporine for the indicated periods of time. Particulate 
(containing mitochondria) and cytosolic fractions of the cells were prepared and cytochrome c 
levels were determined by Western blot using specific antibodies and β-actin (cytosol) and porin 
(mitochondria) as a loading control (A). The subcellular distribution of AIF was determined 4h 
after staurosporine addition by confocal microscopy, as described in (A). Images were analyzed to 
determine the co-localization of mitochondrial markers and AIF and the ratio of ‘green’ (AIF) in 
‘red’ (mito-tracker) of 60-80 cells per condition was quantified (B). To measure ROS production, 
macrophages were treated with the indicated stimuli, followed by loading with DCFH for 30min at 
37ºC and its oxidation was monitorized by flow cytometry (C). Using the same treatment, cells 
were loaded with DAF-2 for 30min at 37ºC and its oxidation was determined to measure RNI 
production (D). Data are presented as mean±SD of three different experiments, or a representative 
blot (A) or cell-image (B). aP<0.01 vs. control, bP<0.01 vs. the staurosporine condition (B). 
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*P<0.05 **P<0.01 vs. vehicle-treated cells, #P<0.05, ##P<0.01 vs. the corresponding condition in 
the absence of lipoxin. 
 
 
Figure 4. Changes of apoptotic-related genes and proteins in lipoxin treated cells. RAW 264.7 
cells were incubated with staurosporine (200 ng/ml) and LXA4 (250 nM) and analyzed at the 
indicated times. The protein levels of Bcl-2, Bax, Mcl-1 and x-IAP were determined by Western 
blot. The levels of the p85 subunit of the PI3K were used as control for lane charge (A). After 
densitometric analysis, the ratios between Mcl-1, x-IAP and Bcl-2 vs. Bax were calculated (B). 
Total RNA was analyzed using the Profiler PCR Array System and the SYBR Green/Fluorescein 
qPCR master mix (SuperArray Bioscience), and gene expression was compared with the web-
based software package for the PCR Array System 
(http://www.superarray.com/pcr/arrayanalysis.php). Colorimetric diagram with a selection of the 
apoptosis-related genes analyzed: Genes whose transcription is up/down (red/green) two fold in 
gene expression after staurosporine or lipoxin plus staurosporine treatment vs. control (4h) are 
shown (C). RT-PCR of specific genes of the array was used to validate the data (D). Results show a 
representative blot (n=3; panel A), and the mean±SD of band ratios. *P<0.05; **P<0.01  vs. the 
corresponding condition in the absence of lipoxin. 
 
Figure 5. LXA4 attenuation of macrophage apoptosis involves Akt and ERK/Nrf-2 activation. 
Cells were treated as described in Fig. 1, and the phosphorylation of Akt in S473 was analyzed 
following LXA4 challenge. Pre-treatment with 20 μM of the PI3K inhibitor LY294002 inhibited 
Akt phosphorylation (A). The activity of the MAP kinases was followed by Western blot using 
specific antibodies (B); the pERK/ERK band ratio was calculated (C).  Inhibition of PI3K with 10 
μM LY294002 (30min preincubation) or ERK with 1 μM PD098059 (30min preincubation) 
abrogated the LXA4-dependent protection against apoptosis (D). Concomitant to ERK activation, 
Nrf-2 translocated to the nucleus (E) and the activity was increased by MG132 (20 μM; used as 
positive control) and by LXA4, but inhibited in the presence of PD098059 upon transfection with 
an ARE-luc reporter vector (F). LXA4-protection from staurosporine induced apoptosis in 
peritoneal macrophages was attenuated in cells from animals lacking Nrf-2 (G). Data are presented 
as means±SD of four different experiments. *P<0.01 vs. the corresponding condition in the absence 
of lipoxin; aP<0.05 vs. the corresponding condition in the absence of PD098059 (F); bP<0.01 vs. 
the corresponding value in Nrf-2+/+ macrophages (G). 
 
Figure 6. LXA4 attenuates apoptosis in peritoneal murine macrophages and in human 
monocyte/macrophages. Primary cultures of murine peritoneal macrophages (A-C), human 
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peripheral blood monocytes (D, E-left) and the human monocytic cell line THP-1 (E-right) were 
incubated as indicated. When cells were treated with PD098059 (1 μM) or LY294002 (10 μM), 
addition was 30min prior to LXA4 challenge (A,C,D). When Jo2 (1 μg/ml) was used, cells were 
incubated for 24h (C); BocPLP (1 μM) was added 1h prior to lipoxin treatment (B,C). Nrf-2 was 
determined by Western blot using nuclear extracts of peripheral blood human monocytes or THP-1 
cells (E). Results show the mean±SD of four different preparations of cells. *P<0.05; **P<0.01 vs. 
the corresponding condition in the absence of lipoxin. 






